Rodryg R.
- Country
- Poland
- Department
- N/A
Research Overview
- Evaluation of Safety and Efficacy of Elacestrant in Combination Therapies for Patients with Metastatic Breast Cancer: A Phase 1b/2 Open-Label Umbrella Study
- A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
- Phase 1b Evaluation of Imvotamab in Patients with Severe Systemic Lupus Erythematosus
Data & Insights
Has run more than one trial at 783 of 1215 partner sites.
Specializations
Gynecologic Oncology
This investigator specializes in the treatment of advanced gynecological cancers, with particular emphasis on ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma.
- Platinum-resistant ovarian cancer management
- Advanced epithelial ovarian cancer treatment
- Recurrent endometrial cancer therapy
The research focus includes innovative approaches in both first-line and maintenance treatment strategies.
Targeted Therapies
The investigator conducts research in precision medicine approaches, particularly focusing on BRCA-mutated cancers and novel therapeutic combinations.
- PARP inhibitor therapies
- Immunotherapy combinations
- Antibody-drug conjugates
Treatment strategies include novel targeted agents and their integration with established therapies.
Clinical Innovation
The investigator explores maintenance treatment strategies and combination therapies for gynecologic cancers.
- Biomarker-driven treatment selection
- Novel drug combinations
- Treatment resistance mechanisms
Research encompasses both early-phase and advanced clinical trials in gynecologic oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.